Onxeo to Attend Key Investor and Scientific Conferences

Regulatory News:

Onxeo S.A. (Paris:ONXEO) (NASDAQ OMX:ONXEO), (“Onxeo” or “the Company”), a clinical-stage biotechnology company specializing in the development of innovative drugs targeting tumor DNA Damage response (DDR) in oncology, in particular against rare or resistant cancers, today announced that its management team will attend the following key investor and scientific conferences in the coming months:

• Investir Day
  October 15, 2019, Paris, France
  A new event providing shareholders and retail investors with the opportunity to meet and discuss with executives of listed companies. A masterclass session by Judith Greciet, CEO of Onxeo, is scheduled during the event.

• The Galien Medstartup 2019
  October 24, 2019, in New York, NYC, United-States
  The Galien Foundation fosters, recognizes and rewards excellence in scientific innovation to improve the state of human health. Its vision is to be the catalyst for the development of the next generation of innovative treatment and technologies that will impact human health and save lives.

• AACR-NCI-EORTC International Conference on Molecular Targets and Cancer Therapeutics
  October 26-30, 2019, in Boston, MA, United-States
  The premier international meeting featuring novel cancer therapeutics organized by the American Association for Cancer Research (AACR), the National Cancer Institute (NCI) and the European Organisation for Research and Treatment of Cancer (EORTC).

• Direct Dirigeants event with Les Echos – Investir
  November 6, 2019, in Paris, France
  Presentation by Judith Greciet, CEO of Onxeo, to individual investors and shareholders.

• 2^nd Annual DNA Damage Response Therapeutics Summit
  January 29-31, 2019, in Boston, MA, United-States
  The Summit brings together the leading pharma and biotech companies accelerating the development of DNA repair pathway inhibitors, to optimize drug discovery, broaden patient population and generate greater efficacy.

About Onxeo
Onxeo (Euronext Paris, NASDAQ Copenhagen: ONXEO) is a clinical-stage biotechnology company developing innovative oncology drugs targeting tumor DNA-binding functions through unique mechanisms of action in the sought-after field of DNA Damage Response (DDR). The Company is focused on bringing early-stage first-in-class or disruptive compounds from translational research to clinical proof-of-concept, a value-creating inflection point appealing to potential partners.